ArticleFrontiers in cardiovascular medicine2025
Surfactant protein-D is an independent predictor of all-cause mortality in men with peripheral artery disease diagnosed by population-based screening.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Peripheral artery disease (PAD) is a common condition caused by atherosclerosis, which leads to reduced blood flow to the limbs. PAD is associated with major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Surfactant protein-D (SP-D) is a defense lectin expressed in the lungs and vasculature and has been previously associated with PAD. Methods: We aimed to examine the prognostic value of plasma SP-D in relation to MACE, MALE, and all-cause mortality in 913 men with PAD diagnosed through population-based screening. The cohort was divided into low plasma SP-D (<420.4 ng/ml) and high SP-D (≥420.4 ng/ml) based on the 95th percentile of baseline measurements. The data were analyzed using univariate and multivariate Cox regression analyses. Results: SP-D was not associated with MACE or MALE. All-cause mortality was significantly increased in the high SP-D group compared with the low SP-D group (31.1% vs. 14.9%, Discussion: SP-D is not associated with MALE and MACE but is an independent predictor of all-cause mortality in men with PAD diagnosed through population-based screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.